Is Vertex Stock Still a Good Buy?
Over the past ten years or so, Vertex Pharmaceuticals (NASDAQ:…
Buy
59
ADPT Quote, Financials, Valuation and Earnings
Last price:
$7.44
Seasonality move
:
14.07%
Day range:
$7.46 - $7.80
52-week range:
$2.56 - $9.01
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
6.26x
P/B ratio:
5.58x
Volume:
1.7M
Avg. volume:
2.2M
1-year change:
176.73%
Market cap:
$1.1B
Revenue:
$179M
EPS (TTM):
-$1.09
Analysts' Opinion
-
Consensus RatingAdaptive Biotechnologies has received a consensus rating of Buy. The company's average rating is a Buy based on 3 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $9.71, Adaptive Biotechnologies has an estimated upside of 27.65% from its current price of $7.61.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $7.00 representing 100% downside risk from its current price of $7.61.
Fair Value
-
According to the consensus of 4 analysts, Adaptive Biotechnologies has 27.65% upside to fair value with a price target of $9.71 per share.
ADPT vs. S&P 500
-
Over the past 5 trading days, Adaptive Biotechnologies has overperformed the S&P 500 by 7.08% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Adaptive Biotechnologies does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Adaptive Biotechnologies has grown year-over-year revenues for 2 quarters straight. In the most recent quarter Adaptive Biotechnologies reported revenues of $47.5M.
Earnings Growth
-
Adaptive Biotechnologies has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Adaptive Biotechnologies reported earnings per share of -$0.23.
Enterprise value:
908.2M
EV / Invested capital:
--
Price / LTM sales:
6.26x
EV / EBIT:
--
EV / Revenue:
5.07x
PEG ratio (5yr expected):
-0.30x
EV / Free cash flow:
-9.19x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$106.9M
Return On Assets:
-26.9%
Net Income Margin (TTM):
-89.12%
Return On Equity:
-63.77%
Return On Invested Capital:
-63.77%
Operating Margin:
-71.3%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $185.3M | $170.3M | $179M | $45.8M | $47.5M | |
| Gross Profit | $127.4M | $94.7M | $106.9M | $26.2M | $29.4M | |
| Operating Income | -$200.2M | -$201.6M | -$155.3M | -$45.6M | -$33.8M | |
| EBITDA | -$175.2M | -$189.3M | -$128.8M | -$61.1M | -$26.3M | |
| Diluted EPS | -$1.41 | -$1.56 | -$1.09 | -$0.48 | -$0.23 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $726.9M | $402.7M | $562.1M | $410.2M | $283.8M | |
| Total Assets | $1.1B | $923.3M | $856.6M | $661.1M | $539.4M | |
| Current Liabilities | $105.2M | $113.8M | $109.8M | $88M | $98.1M | |
| Total Liabilities | $373.1M | $319.2M | $392.5M | $352.9M | $336.9M | |
| Total Equity | $743.3M | $604.1M | $464.1M | $308.3M | $202.5M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$183.9M | -$156.3M | -$95.2M | -$26.9M | -$12.5M | |
| Cash From Investing | $2.9M | $129.6M | $77.8M | $3.2M | $22.1M | |
| Cash From Financing | $132.3M | $2.2M | $241K | $87K | $127K | |
| Free Cash Flow | -$200.3M | -$167M | -$98.9M | -$28.2M | -$12.6M | |
ADPT
Sector
Market Cap
$1.1B
$34.9M
Price % of 52-Week High
84.46%
44.35%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.82%
1-Year Price Total Return
176.73%
-38.5%
Beta (5-Year)
1.728
0.738
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$7.47
200-day SMA
Buy
Level
$6.04
Bollinger Bands (100)
Buy
Level
6.62 - 8.12
Chaikin Money Flow
Buy
Level
29.5M
20-day SMA
Sell
Level
$7.63
Relative Strength Index (RSI14)
Sell
Level
49.27
ADX Line
Sell
Level
8.89
Williams %R
Neutral
Level
-54.487
50-day SMA
Sell
Level
$7.84
MACD (12, 26)
Sell
Level
-0.05
25-day Aroon Oscillator
Sell
Level
-32
On Balance Volume
Neutral
Level
13.3M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-1.9671)
Sell
CA Score
(Annual)
Level (-1.8012)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (10)
Sell
Ohlson Score
Level (2.8065)
Buy
Piotroski F Score
(Annual)
Level (5)
Sell
Quality Ratio Score
Level (3)
Buy
Fundamental Score
Level (5)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).
Stock Forecast FAQ
In the current month, ADPT has received 3 Buy ratings 1 Hold ratings, and 0 Sell ratings. The ADPT average analyst price target in the past 3 months is $9.71.
-
Where Will Adaptive Biotechnologies Stock Be In 1 Year?
According to analysts, the consensus estimate is that Adaptive Biotechnologies share price will rise to $9.71 per share over the next 12 months.
-
What Do Analysts Say About Adaptive Biotechnologies?
Analysts are divided on their view about Adaptive Biotechnologies share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Adaptive Biotechnologies is a Sell and believe this share price will drop from its current level to $7.00.
-
What Is Adaptive Biotechnologies's Price Target?
The price target for Adaptive Biotechnologies over the next 1-year time period is forecast to be $9.71 according to 4 Wall Street analysts, 3 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is ADPT A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Adaptive Biotechnologies is a Buy. 3 of 4 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of ADPT?
You can purchase shares of Adaptive Biotechnologies via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Adaptive Biotechnologies shares.
-
What Is The Adaptive Biotechnologies Share Price Today?
Adaptive Biotechnologies was last trading at $7.44 per share. This represents the most recent stock quote for Adaptive Biotechnologies. Yesterday, Adaptive Biotechnologies closed at $7.61 per share.
-
How To Buy Adaptive Biotechnologies Stock Online?
In order to purchase Adaptive Biotechnologies stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Okta Stock Finally Gaining Investor Confidence?
Given how digital transformation has proliferated, cyberattacks have also been…
Is The Trade Desk the Best Advertising Stock Now?
The worldly backdrop is now shrouded in heavy uncertainty and…
Stock Ideas
Buy
59
Is AAPL Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 35x
Buy
58
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Buy
55
Is NVDA Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 37x
Alerts
Buy
85
HIMS alert for Apr 30
Hims & Hers Health [HIMS] is down 5.31% over the past day.
Buy
54
EAT alert for Apr 30
Brinker International [EAT] is down 2.58% over the past day.
Sell
16
NSP alert for Apr 30
Insperity [NSP] is down 5.13% over the past day.
